AVANIR Pharmaceuticals (AVNR) Announces Agreement to Sell Portfolio of Human Monoclonal Anthrax Antibodies
AVANIR, a pharmaceutical company focused on acquiring, developing, and commercializing novel therapeutic products for the treatment of chronic diseases, announced that it has carried out a definite agreement to sell its collection of human monoclonal anthrax antibodies to Emergent BioSolutions. Emergent also acquired AVANIR’s AVP-21D9 (a fully human monoclonal antibody developed using the Xenerex Technology platform and AVANIR’s lead candidate) as well as other anthrax antibodies. Potentially, AVANIR may receive up to $1.75 million in upfront payments, including royalties on annual net sales if the product goes commercial. Greg Flesher, Vice President of Business Development for AVANIR Pharmaceuticals said, “Emergent…